Key result
FDA approves tirzepatide to reduce MACE risk in high-risk adults with type 2 diabetes.
Why the study?
Tirzepatide was approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk.
Does tirzepatide reduce the risk of MACE in adults with type 2 diabetes at high risk for these events?
Does tirzepatide reduce the risk of MACE in adults with type 2 diabetes at high risk for these events?
Tirzepatide has received a new FDA indication for cardiovascular risk reduction (MACE) in high-risk adults with type 2 diabetes.
May inform tirzepatide prescribing for MACE reduction in high-risk type 2 diabetes; leaves open need for confirmatory outcome trials.
The injectable GIP/GLP-1 receptor agonist tirzepatide (Mounjaro – Lilly), which was approved by the FDA in 2022 for treatment of type 2 diabetes,1 has now been approved to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events. Tirzepatide is also available as Zepbound for chronic weight management and for treatment of obstructive sleep apnea in adults with obesity.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied Type 2 diabetes at high cardiovascular risk. Tirzepatide was evaluated on Major adverse cardiovascular events (MACE). The FDA has approved the GIP/GLP-1 receptor agonist tirzepatide (Mounjaro) to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: